Achieving consistency in fill and finish for cell therapies

Min Sung Park is a process development scientist at Charles River Laboratories. He has a strong background in tissue engineering and regenerative medicine. His projects have included MSCs, primary immune cells, and various mammalian cells. He obtained his PhD from the  school of medicine at Yonsei University in South Korea, where he studied developmental biology, stem cell biology, and tissue engineering for skeletal tissue regeneration in department of orthopedic surgery. As a postdoc fellow, he studied stem cell therapy for treatment of several diseases including cancer, and adipose tissue metabolism. After his postdoc fellowship, he worked in both clinical and industry settings, prior to joining CRL for novel biologics R&D such as cells-, gene- and tissue-based therapeutics products for cancer, autoimmune diseases, and sport medicine/orthopedic indications.

Meredith works at Charles River’s Hanover, MD site, a contract manufacturing and development organization (CDMO) that focuses on cell and gene therapies. Her projects have included mesenchymal stem cells, cancer cell lines, and primary immune cells.

Meredith has a PhD in Biology from Johns Hopkins University and an MS in Healthcare Management from Johns Hopkins Carey Business School. Her post-doctoral fellowship research projects at Johns Hopkins School of Medicine and at the National Institute on Aging focused on T cell activation and anergy induction. Before joining Johns Hopkins as a faculty member, Meredith gained scientific publication experience working on the editorial staff of the Journal of Immunology.